|
Global monoclonal antibody therapeutics market is expected to grow with a CAGR of 12.80% over the forecast period from 2019-2025
Tuesday, June 18, 2019
NEW YORK, June 18, 2019 /PRNewswire/ --
The report on the global monoclonal antibody therapeutics market provides qualitative and quantitative analysis for the period from 2017 to 2025.
Read the full report: https://www.reportlinker.com/p05775053/?utm_source=PRN
The report predicts the global monoclonal antibody therapeutics market to grow with a CAGR of 12.80% over the forecast period from 2019-2025. The study on monoclonal antibody therapeutics market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025.
The report on monoclonal antibody therapeutics market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global monoclonal antibody therapeutics market over the period of 2017 to 2025. Moreover, the report is a collective presentation of primary and secondary research findings.
Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global monoclonal antibody therapeutics market over the period of 2017 to 2025. Further, the IGR- Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.
Report Findings
1) Drivers
-- Growing adoption of monoclonal antibody therapeutics in cancer treatments
-- Increasing approvals of monoclonal antibodies
-- Rising use of monoclonal antibodies for the treatment of autoimmune diseases
2) Restraints
-- High cost
3) Opportunities
-- Increasing investment in research and development
Research Methodology
A) Primary Research
Our primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include
1. Key Opinion Leaders associated with Infinium Global Research
2. Internal and External subject matter experts
3. Professionals and participants from the industry
Our primary research respondents typically include
1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/ country managers
5. Vice President level executives.
B) Secondary Research
Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. At Infinium Global Research, each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.
The secondary sources of the data typically include
1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies
Segment Covered
The global monoclonal antibody therapeutics market is segmented on the basis of end users, based on source, and application.
The Global Monoclonal Antibody Therapeutics Market by End Users
-- Research Institute
-- Private Clinics
-- Hospitals
The Global Monoclonal Antibody Therapeutics Market by Based On Source
-- Humanized
-- Human
-- Chimeric
-- Others
The Global Monoclonal Antibody Therapeutics Market by Application
-- Cancer
-- Ophthalmological Diseases
-- Haematological Diseases
-- Infectious Diseases
-- Autoimmune Diseases
-- Others
Company Profiles
-- Novartis AG
-- Amgen Inc.
-- AbbVie Inc.
-- Bristol-Myers Squibb Company
-- Merck Sharp & Dohme Corp.,
-- Sanofi
-- F. Hoffmann-La Roche Ltd
-- Pfizer Inc
-- Bayer AG
-- GlaxoSmithKline Plc
What does this report deliver?
1. Comprehensive analysis of the global as well as regional markets of the monoclonal antibody therapeutics market.
2. Complete coverage of all the segments in the monoclonal antibody therapeutics market to analyze the trends, developments in the global market and forecast of market size up to 2025.
3. Comprehensive analysis of the companies operating in the global monoclonal antibody therapeutics market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and the latest developments of the company.
4. IGR- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.
Read the full report: https://www.reportlinker.com/p05775053/?utm_source=PRN
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001
View original content:http://www.prnewswire.com/news-releases/global-monoclonal-antibody-therapeutics-market-is-expected-to-grow-with-a-cagr-of-12-80-over-the-forecast-period-from-2019-2025--300870673.html
SOURCE Reportlinker
|
|
|
|
|
|
 |
Pedia.com Releases White Paper on Historic Offering, Underscores the Power of Credibility Marketing | Apr 26, 2024
|
|
Tier One Auto Suppliers Must Evolve with the Supply Chain to Access the 2030 US$15 Billion Next-Gen Cockpit Domain Controller Market | Apr 26, 2024
|
|
RightOfTheDot Set to Host Groundbreaking Digital Asset Auction at NamesCon 2024 Featuring Super Premium Web2 and Web3 Digital Assets | Apr 26, 2024
|
|
Global Kids' Eyewear Market to reach a valuation of US$ 77.0 billion by 2034, FMI Projection | Apr 26, 2024
|
|
Listen Notes, Inc. Rolls Out Listen411: Redefining Podcast Transcription with A.I. Technology | Apr 26, 2024
|
|
AIShield Announces Groundbreaking AI Security Platform SecureAIx with Global Strategic Partners at GISEC 2024 | Apr 26, 2024
|
|
Cirrus by Panasonic® 2.0 Connected Vehicle Platform Advances Roadway Intelligence with Two-Way Communication and Insights That Traffic Operators Need | Apr 26, 2024
|
|
DFIN Completes Its First Tailored Shareholder Reports Test Filing Through ArcReporting | Apr 26, 2024
|
|
Tektronix unveils SignalVu Spectrum Analyzer Software Version 5.4 for analysis of up to eight simultaneous signals, improving multi-signal analysis capabilities for engineers | Apr 26, 2024
|
|
Millwright Holdings Announces Crystal Woody to Lead Actual Agency as Managing Director | Apr 26, 2024
|
|
|
|
